Table 1 Clinicopathological features of 50 cases biopsied/resected to recurrence
From: The effect of smoking on biological change of recurrent breast cancer
Parameters | Number of patients (n = 50) (%) |
|---|---|
Age at operation (years old) | 60 (37–79) |
Tumor size (mm) | 21.8 (8.0–45.0) |
Lymph node metastasis | |
 N0/N1/N2 | 43 (86.0%)/5 (10.0%)/2 (4.0%) |
Estrogen receptor (ER) of primary tumor | |
 Negative/positive | 13 (26.0%)/37 (74.0%) |
Progesterone receptor (PgR) of primary tumor | |
 Negative/positive | 15 (30.0%)/35 (70.0%) |
HER2 of primary tumor | |
 Negative/positive | 48 (96.0%)/2 (4.0%) |
Ki67 of primary tumor | |
 ≤14%/> 14% | 19 (38.0%)/31 (62.0%) |
Intrinsic subtype | |
 HRBC/HER2BC/TNBC | 38 (76.0%)/2 (4.0%)/10 (20.0%) |
Chemotherapy after surgery | |
 No/yes | 37 (74.0%)/13 (26.0%) |
Endocrine therapy after surgery | |
 No/yes | 14 (28.0%)/36 (72.0%) |
Radiation therapy after surgery | |
 No/yes | 39 (78.0%)/11 (22.0%) |
Trastuzumab after surgery | |
 No/yes | 49 (98.0%)/1 (2.0%) |
No-treatment after surgery | |
 No/yes | 44 (88.0%)/6 (12.0%) |
Age at recurrence (years old) | 62 (41–86) |
Recurrent tumor site biopsied | |
 Local/regional lymph node/lung/brain/liver | 30 (60.0%)/15 (30.0%)/3 (6.0%)/1 (2.0%)/1 (2.0%) |
Change in expression of ER in recurrent tumor | |
 Negative conversion/no change/positive conversion | 3 (6.0%)/46 (92.0%)/1 (2.0%) |
Change in expression of PgR in recurrent tumor | |
 Negative conversion/no change/positive conversion | 15 (30.0%)/35 (70.0%)/0 (0.0%) |
Change in expression of HER2 in recurrent tumor | |
 Negative conversion/no change/positive conversion | 0 (0.0%)/44 (88.0%)/6 (12.0%) |
Change of intrinsic subtype in recurrent tumor | |
 No/yes | 45 (90.0%)/5 (10.0%) |
 Disease free survival | 792 (99–3300) |
Smoker | |
 No/yes | 36 (72.0%)/14 (28.0%) |
 Pack-years of smoker | 30 (1.4–150) |